At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CNTX Context Therapeutics Inc.
Closed 05-14 16:00:00 EDT
1.71
+0.03
+1.79%
盘后1.73
+0.02+1.11%
19:27 EDT
High1.74
Low1.63
Vol101.35K
Open1.66
D1 Closing1.68
Amplitude6.51%
Mkt Cap128.25M
Tradable Cap124.70M
Total Shares75.00M
T/O170.50K
T/O Rate0.14%
Tradable Shares72.92M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Context Therapeutics Inc. (CNTX) Upgraded to Buy: Here's Why
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.